A phase I clinical trial (NCT03772899) evaluating the combination of FMT from healthy donors (HD) with anti-PD-1 therapy in treatment-naive patients with advanced melanoma demonstrated objective responses in 13 patients (65%), comprising 4 (20%) CR and 9 (45%) PR. This evidence concerns the gene PDCD1 and melanoma.